NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

20/20 Biolabs, Inc. (AIDX) Stock Analysis

20/20 Biolabs, Inc. (AIDX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

AIDX

$0.59

−$0.02 (−3.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AIDX with… →

AIDX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.59
Previous Close
$0.61
Day's Range
0.58–0.62
52-Week Range
0.40–50.00
Volume
131.40K
Valuation
Market Cap
$7.55M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.70
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.57
Financials (FY)
Revenue (FY)
$2.05M+16.71%
Net Income (FY)
−$3.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
−285.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.77M
Dividend and dates
Avg Volume
637.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AIDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.05M−$3.74M−182.8%
2024$1.75M−$5.55M−316.8%
2023$1.42M−$6.39M−448.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.05M$604.54K−$3.33M−$3.74M−182.8%
2024$1.75M$360.31K−$5.66M−$5.55M−316.8%
2023$1.42M$109.14K−$6.36M−$6.39M−448.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AIDX Valuation vs Medical Devices Median

Median of 151 stocks
MetricAIDXMedical Devices medianvs median
P/S ratio3.702.9824% above
Profit margin−285.00%−1.69%283.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

20/20 Biolabs, Inc. (AIDX) is capitalised at $7.55M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 4.

The most recent close on file for AIDX is $0.59, dated September 4, 2026. That is −$0.02 (−3.28%) against the previous close. Over the past 52 weeks the price has ranged from $0.40 to $50.00. The latest close sits 47.5% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.05M. That is +16.71% against the prior fiscal year, when revenue was $1.75M. The same year closed with a net loss of $3.74M. The reported profit margin is −285%. That is 283.3 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.57.

Across the 3 fiscal years on file, revenue moves from $1.42M in 2023 to $2.05M in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 3.7. On price-to-sales that is 24.41% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The stored price history starts on February 19, 2026, and the total return since then is −97.53%.

Growth & Income

No dividend is on file for AIDX.

So far in 2026 the price is −97.53%.

Peer Comparison

20/20 Biolabs, Inc. (AIDX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
20/20 Biolabs, Inc. AIDX $7.55M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. 20/20 Biolabs, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Visit website →